In this episode of our biotech podcast, we sit down with Patrick Most – biotech entrepreneur, founder of Aavigen, and professor of cardiology in Heidelberg University, Germany. Together, we explore his journey, insights into gene therapy, and how it will change the therapeutic landscape.Hosted by Meronn and Pierre00:00:00 Intro00:01:40 Why gene therapy?00:03:20 From Academia to Biotech00:12:20 pitching a startup00:13:30 pitfalls when translating academic findings00:17:00 Accessibility of gene therapy00:19:40 Viruses to cure diseases???00:28:00 AI in gene therapy00:30:40 Business model00:34:05 Clearing misconceptions00:36:10 Patience as a biotech founder00:43:10 Day to day as professor and biotech founder00:45:00 Spinning out early or later?00:47:00 The role of a CEO00:51:35 Choosing Co-Founders00:54:10 Corona00:56:00 Biotech winter00:58:30 Networking01:01:00 How to get started as a student01:02:45 Impact of being a CEO on professor and vice versa01:05:00 US vs. Germany01:08:00 Doing something differently?01:10:03 When will Gene therapy cure heart disease?01:13:00 Conclusion#genetherapy #biotechnology #PatrickMost #transcribed #AAV #virus #research #professor #Heidelberg #innovation